Download this White Paper to Learn More

As gene therapy scales up, efficient and compliant bioprocessing becomes critical — especially in viral vector production using adeno-associated virus (AAV) and lentivirus (LV). A key challenge is the cell lysis step, traditionally dependent on Triton™ X-100 — now restricted under EU REACH regulations due to safety concerns.

Access this valuable resource to discover the latest solutions for addressing this critical issue and keep your organization aligned with evolving global regulatory standards. We explore:

• Next-generation reagents, and how they compare to Triton X-100 and polysorbate 20
• How to deliver more simplified handling and reduced manual steps
• Ways to ensure regulatory compliance
• Approaches that drive high process performance, including effective lysis and viral vector recovery and maintenance of particle integrity
• And more

Don’t miss key insights on scalable, compliant, and high-performing alternatives for modern viral vector manufacturing — enabling streamlined workflows from harvest to purification. Download now!